Colorectal disorders:
Indications for ROWASA:
Mild to moderate distal ulcerative colitis, proctosigmoiditis, proctitis.
Adult Dosage:
4g (60mL) daily at bedtime for 3–6 weeks. Retain enema for 8 hours.
Children Dosage:
Not established.
ROWASA Warnings/Precautions:
Sulfite sensitivity. Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.
ROWASA Classification:
Salicylate.
ROWASA Interactions:
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.
Adverse Reactions:
Abdominal pain/cramps/discomfort, headache, flatulence, nausea, diarrhea, flu, malaise, fever, sore throat, dizziness, bloating, joint, back, or rectal pain, hemorrhoids, itching, constipation, hair loss, pancolitis, pericarditis, rash; renal impairment, acute intolerance syndrome, hypersensitivity reactions (including myocarditis, pericarditis, pneumonitis, hematologic abnormalities, others).
Generic Drug Availability:
YES
How Supplied:
Enema—7, 14, 28
